Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly 500 HCV-infected kidneys are discarded annually in the United States. Due the opioid epidemic, the number of HCV-infected donors has increased because of a rise in both new HCV infections and drugrelated deaths. In the past 5 years, HCV has been transformed into a curable illness with direct-acting antiviral therapies (DAAs) that are effective in >95% of patients treated and are extremely well tolerated. Recent data has shown several direct-acting antiviral combinations are safe and effective after kidney transplant, and can achieve the same high cure rate seen in the general population and without increasing the rate of acute rejection. Because of this, strategies to decrease discard of HCVinfected organs have been devised. Two recent studies have transplanted HCV-uninfected dialysis patients with kidneys from donors actively infected with HCV; recipients were treated with DAA in the peri-transplant period. More research is needed to determine the safety and efficacy of this approach, but it has the potential to dramatically increase the donor pool of available kidneys, shorten waitlist times and ultimately decreases mortality in patients waiting for kidney transplant.
INTRODUCTION
According to the Organ Procurement and Transplantation Network (OPTN), over 100,000 patients are waiting for a kidney transplant. This number continues to increases each year by 2%-10%. 1 In many parts of the country, patients are told to expect waiting times that exceed 5-7 years; some wait longer if they have been previously sensitized to human leukocyte antigens. Because of long wait times combined with the high annual rate of mortality on dialysis, it is estimated that more than 25% of patients on the waitlist will die prior to getting a kidney transplant. 1 Because of this, strategies to increase organ allocation are being urgently explored. Due to the opioid crisis facing the United States and many other countries worldwide, hepatitis C virus (HCV) infected deceased donors are increasingly becoming available for transplantation. A Centers for Disease Control (CDC) analysis estimated 34,000 "acute" cases of hepatitis C occurred in the United States in 2015, a 2.9-fold increase from 2010 to 2015. 2 In parallel, there has been a dramatically increasing number of overdose deaths in the United States; according to the CDC, there were 64,070 overdose deaths in the United States in 2016, a 21% increase from the year prior. 3 HCV-infected kidneys are currently being underutilized in the United States. In a survey of kidney donations between 1995 and 2009, of the 93,825 HCV-infected deceased donors (potentially 187,650 kidneys), over 60% were discarded. 4 Reese et al. estimated that 500 kidneys per year were unnecessarily discarded between 2005 and 2014 due to HCV antibody positive status of the donor. 5 Multiple studies have shown that the wait time is substantially shorter in patients willing to accept a kidney from an HCV-infected donor. 6 Waitlist time and duration of dialysis contribute greatly to outcomes following kidney transplantation; thus, shortening wait time also decreases patients' exposure to the detrimental effects of end-stage renal disease (ESRD) and their impact on post-transplant outcomes. 7 Therefore, it is of paramount importance that we develop strategies to utilize these kidneys for transplantation. This is in accordance with the OPTN Final Rule that available resources are used efficiently; namely, that all potentially transplantable organs are recognized for their enormous value as scarce resources and should be utilized to their maximum potential for the maximum benefit. 8 
THE EFFECT OF HCV INFECTION ON TRANSPLANT OUTCOMES
Chronic HCV infection has been independently associated with a number of adverse outcomes in kidney transplant recipients, including increased risk of acute rejection, chronic allograft nephropathy, diabetes, and de novo glomerulonephritis. [9] [10] [11] [12] [13] Meta-analyses have demonstrated a 1.56-fold (1.35-1.80) relative risk of graft loss and 1.79-fold (1.57-2.03) relative risk for mortality when compared to uninfected kidney transplant recipients. [14] [15] [16] However, despite reductions in graft and overall survival, it is still unequivocally clear that patients with HCV benefit from transplant as compared to remaining on dialysis on the waitlist. 17 The majority of studies have shown that survival differences between HCV-infected and uninfected kidney transplant recipients do not typically manifest until more than 10 years of follow-up. 15, 18 More recent studies have shown no difference in graft survival or function in recipients of HCV-infected deceased donor kidney transplants compared to those receiving HCV-uninfected deceased donor transplants. 6 It is important to note that all of the studies that have looked at post-transplant outcomes in HCV-infected kidney transplant recipients were performed in a historical era where HCV remained largely untreatable after kidney transplant. This was due to the poor efficacy, significant side effect profile, including the risk of provoking acute rejection, associated with interferon (IFN)-based therapies for HCV. Rates of viral cure in kidney transplant recipients infected with HCV treated with IFN-based therapy were poor, ranging between 12.5% and 41% depending on whether IFN monotherapy vs. combination of pegylated IFN and ribavirin were used. 19 IFN-based treatments were difficult to tolerate post-transplant; on average, 21% of kidney transplant recipients treated with a IFNbased regimen stopped treatment due to side effects and the rates of acute rejection varied from 0% to 40% (average 7%) in patients treated with IFN. 19 With the recent surge in HCV-infected donors, and because these organs are currently only used for HCVinfected dialysis patients; the supply exceeds the demand. Because of this, there is a general notion that the accepting transplant center is likely to be more selective in accepting a HCV-infected kidney-it has been observed in some studies that a lower proportion of HCV-infected organs are procured after cardiac death compared to non-HCV-infected organs. 6 Additionally, the age of the average HCV-infected donor is declining, thus the available HCV-infected organs may have more favorable characteristics. 1 
TREATING HCV WITH DIRECT-ACTING ANTIVIRAL THERAPIES AFTER KIDNEY TRANSPLANTATION
The approval of direct-acting antiviral therapies (DAAs) has revolutionized the management of HCV and has made it possible to eradication HCV after kidney transplant in >95% who undergo treatment. The current approach for curative treatment is to target multiple components of HCV's replicative machinery (NS3-4A protease, NS5A protein, or NS5B polymerase) with agents from 2 or more classes, and inhibit them for 8-24 weeks. Patients with all genotypes of HCV infection and any level of chronic kidney disease can now be treated with DAA therapies that are IFNfree. [20] [21] [22] [23] The vast majority of these combinations are also ribavirin-free. There are now only a few situations where ribavirin is still used in conjunction with DAAs, such as in decompensated liver disease or after liver transplantation. 25, 26 There is increasing data that DAAs can be successfully used in kidney transplant recipients with low rates of adverse events and without increasing the rate of acute rejection (Table 1 and S1). Results from 2 prospective clinical trials and 10 retrospective series of kidney transplant recipients demonstrated that more than 97% were cured with DAAs and the rate of acute rejection was less than 2%. 9, 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] It is important to note that nearly one-third needed adjustment in calcineurin inhibitor dose during or shortly after stopping DAA therapy, suggesting extremely close monitoring of calcineurin inhibitor levels is needed, particularly if treatment is occurring in the early post-transplant period.
DETERMINING INFECTIVITY OF THE DONOR
United States Public Health Service guidelines now recommend HCV nucleic acid testing (NAT) for screening of all deceased donors prior to organ procurement; this is also known as HCV RNA or HCV viral load testing. 36 Prior to offering an organ, the Regional organ procurement organization (OPO) is aware of both the status of the HCV antibody and NAT testing. Patients with HCV antibody positivity and positive HCV NAT should be considered to have an active infection ( Table 2 ). The risk of HCV transmission is extremely high, nearly universal in these cases. Patients with positive HCV antibody test and negative NAT (HCV AB 1 NAT-) are not considered to have active HCV infection ( Table 2 ). The most common reasons for finding a positive HCV antibody test and a negative NAT are prior HCV exposure that either spontaneously cleared (up to 30% of all exposed to HCV) or an infection that was previously successfully treated and the virus was eradicated. 37 In either of these situations the HCV antibody remains positive for life despite negative NAT. Rarely, there may be a false positive HCV antibody, which may occur in some autoimmune conditions such as rheumatoid arthritis or systemic lupus erythematosus. 38, 39 Finally it is possible the patient has a false negative NAT test and may be infectious. The NAT test may be falsely negative for the first 7-10 days after an infection occurs; this is called the "eclipse phase," when HCV infection might go undetected by NAT testing. 40 Because of the small chance that the patient has a false negative HCV NAT and may be able to transmit HCV infection, many OPOs treat HCV Ab 1 NAT-organs as "HCV infected" in the allocation system. However, transmission risk is clearly much lower in cases of HCV antibody positivity with negative NAT testing, thus strategies to increase utilization of these organs are desperately needed.
STRATEGIES TO INCREASE UTILIZATION OF HCV-INFECTED KIDNEYS Transplanting HCV NAT positive kidneys in HCV-uninfected recipients
The ability to cure HCV with DAAs has opened the door to clinical trials that investigate whether transplantation from HCV-infected donors, with active viremia, followed by immediate post-transplant treatment can cure HCV in the recipient without leading to adverse events. Since HCV infection is truly eradicated when it is cured and does not relapse, this strategy may be acceptable to patients interested in shortening their time on the waitlist. A schematic for an approach to managing these patients is shown in Figure 1 . Two published studies exist that have explored these strategies in HCV-uninfected transplant patients. The early results of the THINKER trial showed that HCVinfected organs with positive HCV RNA testing could be transplanted into recipients who do not have HCV infection, and the virus could be eradicated with a 12 week course of DAAs begun shortly after transplant. 41 This open-label, single-arm trial performed by Goldberg and colleagues, transplanted 10 patients without HCV with kidneys from HCV-infected donors with positive HCV NAT testing at the time of transplant. All donors were genotyped prior to transplantation. All recipients developed viremia within 3 days post-transplant. At that time, they immediately began treatment with elbasvir-grazoprevir for twelve weeks. Patients received kidneys from donors with genotype 1 infection, because elbasvir-grazoprevir is not effective at treating genotypes 2 or 3. All patients had a negative HCV RNA by day 30 of therapy and 100% achieved a durable cure of HCV infection. Elbasvir-grazoprevir, which is approved for patients with any level of baseline kidney function, was well tolerated in the immediate post-transplant period. One patient developed focal segmental glomerulosclerosis (FSGS) in the transplanted kidney that was possibly related to DAA therapy. It should be noted that FSGS has been noted in patients with chronic HCV undergoing DAA therapy in 2 other series. 32, 42 There is limited data on how patients with FSGS induced by DAAs should be managed, or if discontinuing DAA therapy improves outcomes. Once sufficient clinical trial data is available to determine the safety of strategies to transplant HCV infected kidneys into HCV uninfected kidneys the potential expanded use of these organs is listed in this column. The EXPANDER-1 trial has reported 8 HCV-positive kidney transplant recipients with preemptive HCV treatment beginning at the time of transplantation from a HCV-infected donor. Final data are not currently available, but data presented in abstract form demonstrated all had negative viral loads on DAA therapy and 6/6 had sufficient follow-up to determine that HCV had been cured. 43 There were no treatment-related severe adverse events reported thus far in the EXPANDER trial.
Other centers, including ours, are investigating similar strategies to transplant HCV-infected kidneys into HCVnegative recipients (NCT02945150). At our center, patients who still have substantial remaining waitlist time are invited to undergo an education session and informed consent by a physician investigator and are then evaluated for readiness for transplantation. Once they are deemed medically cleared for transplantation, their status is switched to "willing to accept an HCV-infected organ" in the UNOS database. At the time of transplantation from an HCV-infected donor with genotype 1 or 4 infection, the patient begins preemptive elbasvir and grazoprevir "on-call" to the operating room and in the early post-transplantation period.
An ideal regimen to treat HCV infection in the immediate post-kidney transplant recipient would need to be safe in patients with low eGFR so it could be used in patients with delayed graft function, should have few to no interactions with immunosuppressant medications, and ideally treat all genotypes of HCV infection, thus obviating the need for rapid genotyping of donors prior to transplantation. The safety and cost effectiveness of this approach needs to be defined in future, larger studies; however, this strategy has the potential to substantially expand the donor pool, impacting hundreds of lives each year.
Transplanting HCV antibody positive, NAT negative kidneys into uninfected recipients
As discussed earlier, it is likely that the majority of HCV AB 1 NAT-kidneys could be utilized for transplantation without ever posing a risk of HCV transmission. However, given the small risk of false negative NAT, extremely close monitoring of HCV RNA needs to occur after transplant. If HCV transmission does occur, immediate treatment with genotype-based standard-of-care DAA therapy should eliminate HCV infection (Figure 2) .
The optimal frequency and duration of surveillance for HCV after transplantation with an AB 1 NAT-donor is unknown and should be defined with prospective studies. Published report of cases of HCV from increased risk donors with false negative NAT screening to recipients of solid organs were all detected within 12 weeks after transplantation. In fact, several cases were detected within the first month post-transplant. 44 We propose research protocols that employ monthly screening for HCV RNA for at least 6 months after transplant from a HCV AB 1 NATdonor ( Figure 2 ). If transmission of HCV infection has occurred, the patient would need to be ensured access to expeditious genotype-based, standard-of-care DAA treatment as soon as possible. More data is needed on strategies Figure 1 Schematic for management of a patients undergoing kidney transplantation from a HCV-infected donor with a positive nucleic acid test. The optimal time to initiate DAA therapy after kidney transplantation from a HCV NAT1 donor is unknown, the authors' suggest starting on-call to the operating room or immediately post-transplant. Patients need to be carefully followed for compliance and adverse events while on DAAs. *DAA therapy may be between 8 and 24 weeks depending on the DAA regimen selected. **Test for cure should be performed 12 weeks after completing DAAs. HCV 5 hepatitis c virus; DAA 5 direct-acting antiviral; NAT 5 nucleic acid test. Figure 2 Schematic for monitoring and management of a patients undergoing kidney transplantation from a HCV Antibody positive, nucleic acid test negative donor. The optimal frequency and duration of HCV testing after transplantation from a HCV AB1NAT-donor is unknown, the above represents the authors' opinion. *Genotype-based therapy may be between 8 and 24 weeks depending on the DAA regimen selected. **Test for cure should be performed 12 weeks after completing DAAs. AB1NAT-5 HCV antibody positive, nucleic acid test negative; DAAs5direct-acting antiviral therapies; HCV 5 hepatitis C virus; RNA 5 ribonucleic acid.
that utilize AB 1 NAT-donors for uninfected recipients followed by active surveillance. Patients need to be educated on the potential risk of this strategy and sign informed consent prior to receiving an AB 1 NAT-transplant.
Potential risks
Acute HCV infection is generally asymptomatic, but rarely can cause fulminant hepatic failure, defined by severe impairment of hepatic function with necrosis of hepatocytes in the absence of preexisting liver disease. This may, rarely result in a fatal outcome. 45 Fibrosing cholestatic hepatitis is another devastating complication of transplantation in an HCV-infected kidney transplant. 46, 47 This disease typically affects immunosuppressed patients and is characterized by aggressive cholestasis leading to rapidly progressive hepatic failure with characteristic histopathological findings of peri-portal fibrosis, ballooning degeneration of hepatocytes and cholestasis, with minimal inflammation on biopsy. It is necessary that treatment with DAAs begin soon after the transplant to prevent these potential early complications. The closer to the time of transplant that DAA therapy is started the better, however it is unlikely that a short delay (within the first 3 days post-transplant as was done in the THINKER trial) would increase the risk of fulminant cholestatic hepatitis. Currently, the safety of longer delays in starting treatment, for example such as those that exceed the first week, are unknown.
Other than these 2 rare early presentations, infection with HCV generally leads to chronic hepatitis that typically progresses slowly to cirrhosis over the span of 20-30 years. Immunosuppression, however, may speed the progression to cirrhosis. Though mixed cryoglobulinemia syndrome occurs in rarely in the setting of HCV infection, patients should be informed of the risk of experiencing this syndrome that is characterized by arthritis, neuropathy, rashes, and immune-complex mediated glomerulonephritis should they develop HCV infection after the transplant. [48] [49] [50] Patients should be informed that there is a risk that the testing used to genotype the donor could be inaccurate, or that the patient could have a "mixed infection" with 2 genotypes circulating and the less dominant genotype may not be detected on initial testing. Thus, there is a risk that the treatment prescribed may not be effective for the donor's infection. For this reason, using a pan-genotypic regimen, such as glecaprevir/pibrentasvir, would be optimal.
It is also possible that a breakthrough infection could occur and that the virus could develop resistance mutations. In this circumstance, retreatment protocols have been recommended: recent data show that "salvage regimens" are now available and can successfully treat those patients who have failed first-line DAA therapy. 51, 52 Household and sexual partners may question their risk of acquiring HCV infection. Avoiding blood exposure (i.e., avoiding sharing razors and toothbrushes) should be recommended until the patient has been deemed cleared of HCV with a negative viral load test 12 weeks after completing DAA therapy. Sexual transmission is rare: a study of 500 HIV-negative couples where one partner had HCV infection and the other did not, demonstrated that HCV transmission occurred in approximately one per 190,000 sexual contacts. 53 In the general HCV-infected population, side effects of DAA therapies are relatively mild, with typically no more than 15% experiencing headache, nausea or fatigue. Typically, less than 2 out of 100 patients discontinue therapy due to side effects. Side effects in the postkidney transplant setting may be more frequent or severe, although data from the twelve available series in kidney transplant recipients do not suggest a dramatic increase in side effects (Table S1 ). The only potentially treatment-related serious adverse event in the THINKER trial was development of FSGS in the transplanted kidney.
Who is the right recipient of an HCV-infected transplant?
First and foremost, patients with known HCV infection who are waiting for a deceased donor transplant should be offered the opportunity to accept an HCV-infected donor kidney so that they can be transplanted sooner; approximately 6% of the waitlist is HCV infected according to recent data. 54 At this time, HCV-uninfected recipients who are offered a kidney from an HCV-infected donor should be those on the transplant list with substantial wait time remaining in order to maximize potential benefit. In order to be enrolled in the THINKER study, patients had to have no more than 1.5 years of accumulated wait time. In our view, however, the cutoff parameters used to evaluate a patient's candidacy should be individualized and based on the patients age, blood type, prior sensitization, and the transplant center's expected wait time.
Informed consent prior to transplant with an HCV-infected organ is a critical aspect of any program promoting transplantation of HCV-infected kidneys into uninfected recipients. While the THINKER and EXPANDER trials have so far shown 100% cure rates with DAAs, it is necessary to inform patients that the numbers who have undergone this protocol are still very small. Patients included in the THINKER and EXPANDER studies went through extensive screening, education, and also that the 10 patients at each site were a fairly small proportion of the total who were evaluated for the program. At this point, HCV infected to uninfected transplantation should only occur as a part of a clinical trial, in collaboration with investigators that have extensive experience with DAAs.
As noted earlier, severe acute complications of HCV viremia include acute fulminant hepatitis or fibrosing cholestatic hepatitis. Because of the small but theoretical risk of these devastating complications, patients who undergo HCV-infected transplantation should also meet criteria for liver transplant candidacy should it be needed.
Ensuring availability of DAA therapy post-transplant
Because the safety and efficacy of transplanting HCV-infected organs into uninfected recipients needs to be further defined with larger studies, we currently recommend it be performed only in patients who give informed consent and have definite and immediate access to DAA therapy post-transplant. Ideally, at the present time, this should be done as a part of a research protocol. Both the THINKER and EXPANDER studies have had DAA available by the study sponsor (Merck) and did not have to rely on obtaining insurer approval of DAA therapy. Given the current cost of DAA therapy, ranging between $26,500-80,000 USD depending on the agent and duration of therapy, the issue of insurance coverage is non-trivial, as access to these agents is often tightly controlled by insurers. Pre-transplantation commitment for posttransplant DAA therapy would be needed from the payor if the drug is not provided as part of a clinical trial.
It is well established that kidney transplantation is cost effective compared to remaining on dialysis. 55 Further research will need to show that the cost-savings of avoiding dialysis far exceeds the cost of DAA therapy. Considering the recent dramatic decrease in wholesale prices for recently-approved DAA therapies, an 8-week course of glecaprevir-pibrentasvir is priced at 26,500 wholesale, we anticipate that this approach will be cost effective.
Areas for future investigation
While the THINKER and EXPANDER trials provide tremendous optimism about using HCV-infected donor organs for patients without HCV infection to decrease organ discard rates and increase the donor pool, more safety data is needed before this approach can be widely adopted. Research should focus on determining which DAA regimen is safest and best tolerated post-transplant. If a pan-genotypic regimen can be used to prevent transmission of all genotypes of HCV, this approach would dramatically streamline the process of organ allocation, obviating the need for rapid-genotyping, and decreasing the risks associated with a possible incorrect genotype test or mixed infection. At this time, following the full treatment course recommended by AASLD/ IDSA and upcoming KDIGO guidelines is prudent. However, given the low level of the virus actually transmitted with the donor kidney, one could speculate that a shorter duration of therapy might be effective at preventing transmission if begun immediately post-transplant. This should be defined by future studies as it could dramatically decrease costs associated with this approach. Strategies for using HCV antibody positive organs that do not have a positive HCV NAT need to be devised and tested, and the transmission rate of HCV with a HCV AB 1 NAT-kidneys needs to be determined in order to inform patients about their risk of HCV transmission. Formal cost-effectiveness analyses should be performed, taking into account the decrease in cost of dialysis, dialysis-related hospitalizations, dialysis access complications, as well as the cost of DAAs, transplantation, and potential post-transplant complications. These efforts should focus on time to transplantation and patients-centered outcomes.
CONCLUSION
On a patient-level, the opportunity to accept an organ from a HCV-infected donor followed by surveillance for HCV and immediate treatment with DAAs or preemptive treatment with DAAs increases access to expedited transplantation, substantially shortening waitlist time and decreasing morbidity and mortality associated with ESRD. On a population level, this can greatly expand the viable kidney donor pool and could result in a substantial reduction in longterm healthcare costs for patients being treated with dialysis who suffer from ESRD and its co-morbid complications. The pool of available HCV infected deceased donors is increasing and the younger age and improving quality of these organs suggests that with immediate eradication of HCV we should be optimistic about expecting equivalent or perhaps improved long-term outcomes with these organs.
Considering these recent advances in HCV therapy, we believe that utilizing AB 1 NAT-organs from high risk donors followed by active surveillance with HCV RNA post-transplant or transplanting a HCV NAT1 kidney followed by immediate treatment with DAAs has the potential to play an important role in curtailing the current high discard rates for HCV-positive kidneys.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's Web site: Table S1 . Adverse events reported in at least 5% of patients with chronic HCV infection treated with DAAs after kidney transplantation.
